

July 8, 2016

General Manager
DCS - Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001

COMPANY CODE:

506285

SCRIP ID:

BAYERCROP

Dear Sir,

Sub: Bayer CropScience Limited - Presentation at Investor/ Analyst Meet being held on July 8, 2016

Please find enclosed herewith the presentation that will be made at the Investor/ Analyst Meet of Bayer CropScience Limited being held on Friday, July 8, 2016.

Request you to please take the said presentation on record and upload onto the BSE website.

Kindly acknowledge receipt of the same.

Thanking you,

Bayer CropScience Ltd. CIN: L24210MH1958PLC011173

Registered and Corporate Office: Bayer House Central Avenue Hiranandani Estate Thane (West) – 400 607 Maharashtra, India

Tel: +91 22 2531 1234 Fax: +91 22 2545 5063

www.bayer.in

www.cropscience.bayer.com

Yours faithfully,

for Bayer CropScience Limited

Rajiv Wani

Vice President - Law, Patents & Compliance

& Company Secretary

Encl.: As above



Science For A Better Life





Investor Presentation

Bayer CropScience Ltd.



Forward-Looking Statements

This website/release/presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management.

Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at http://www.bayer.com/.

The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.



Disclaimer

Bayer CropScience Limited in this presentation shall be referred to as BCSL/Company for the sake of simplification.

The information contained herein has been prepared to assist prospective investors and/ or their agents in making their own evaluation of the Company and does not purport to be all-inclusive or to contain all of the information a prospective or existing investor may desire. In all cases, interested parties should conduct their own investigation and analysis of the Company and the data set forth in this information.

BCSL makes no representation or warranty as to the accuracy or completeness of this information and shall not have any liability for any representations (expressed or implied) regarding information contained in, or for any omissions from, this information or any other written or oral communications transmitted to the recipient in the course of its evaluation of the Company.

The first quarter of the financial year 2016-2017 ended on June 30, 2016. BCSL has not published any results or figures for the aforementioned period. Having said that, please understand that we will not comment on the results of the respective period.



Additional information

This communication relates to a proposed offer by Bayer Aktiengesellschaft or its subsidiaries ("Bayer"), to purchase all of the outstanding shares of common stock, par value \$0.01 per share, of Monsanto Company, a Delaware corporation ("Monsanto"). This communication is neither an offer to purchase nor a solicitation of an offer to sell shares of Monsanto. No tender offer for the shares of Monsanto has commenced at this time. At the time a tender offer for the shares of Monsanto is commenced, Bayer will file tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other offer documents) with the Securities and Exchange Commission (the "SEC") with respect to the tender offer. Any definitive tender offer documents will be mailed to the stockholders of Monsanto. STOCKHOLDERS OF MONSANTO ARE URGED TO READ THE RELEVANT TENDER OFFER MATERIALS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE TENDER OFFER THAT STOCKHOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING THE TENDER OF THEIR SHARES. Stockholders of Monsanto will be able to obtain free copies of these documents (if and when available) and other documents filed by Bayer with the SEC through the website maintained by the SEC at www.sec.gov.



Agenda

- Update Bayer global
- Overview of Bayer in India
- Bayer CropScience Ltd. (BCSL): Financial Perspective
- Update Indian Accounting Standards
- BCSL: Business Update


Our Mission Bayer: Science For A Better Life





Science and innovation: Throughout its history, Bayer has reinvented itself time and again





Our business areas The Life Sciences





Pharmaceuticals

Prescription drugs



Consumer Health

 Over-the-counter medicines, dietary supplements, dermatology products, foot care and sunscreen




Crop Science

 Innovative crop protection and seeds

Animal Health*

Group structure and company organisation are being aligned to the Life Sciences focus





Sustainability is an integral part of our corporate strategy and values




- For Bayer sustainability means
 - achieving commercial success while
 - meeting the needs of our employees and society and
 - protecting the environment and natural resources



Effective sustainability management ensures Bayer's "license to operate" and is a proxy for the overall quality of a company's management


Sustainability addresses global trends and challenges and stakeholder expectations






Bayer Group Q1 2016: Life Sciences off to a successful start in 2016







Figures in EUR Mio.

^{*} year-on-year change currency-adjusted






Acquisition of Monsanto to create a global leader in agriculture

Innovation powerhouse to deliver integrated solutions for the next generation of farming

Combination addresses fundamental global challenges






People on the planet by 2050



Declining hectares of farmland per capita by 2050



Rising per capita protein intake by 2024



Biophysical effect of climate change shocks on yields by 2050



Estimated Ag input market size by 2025



Productivity increase required to feed the planet by 2050



Unique and compelling opportunity for Bayer

Strong Fit with Bayer's Strategy

- Reinforces Bayer as a Life Science company with leadership positions in its core business segments
- Targeting an attractive long-term growth industry
- Highly innovative biotech based business addressing unmet scientific need

Integrated Leader in Agriculture

- Combination creates an industry leader in Crop Science with integrated offering of Seeds & Traits, Crop Protection, Biologics and Digital Farming
- Broad product portfolio as well as broad and deep combined R&D pipeline to deliver better solutions for farmers

Significant Value Creation

- ~\$1.5bn total synergies after year three plus additional integrated offer benefits in future years
- Accretion to core EPS by mid-single digit percentage in the first full year after closing and double-digit percentage thereafter
- Potential to command premium valuation for combined Crop Science business via re-rating



Agenda

- Update Bayer global
- Overview of Bayer in India
- Bayer CropScience Ltd. (BCSL): Financial Perspective
- Update Indian Accounting Standards
- BCSL: Business Update



Bayer's Crop Science legal entities in India



Bayer CropScience Ltd.

Sales of Crop Protection products, Environmental Science products and Hybrid Seeds for field crops.

Crop Protection and Environmental Science products partly formulated in-house.



Bayer BioScience Pvt. Ltd.

Research, breeding, production and conditioning of high quality Hybrid Seeds for field crops.



Bayer Vapi Pvt. Ltd.

One of the core manufacturing sites for Bayer's Crop Science division globally, mainly engaged in manufacturing active ingredients and intermediates.



Nunhems India Pvt. Ltd. Breeding, production, conditioning, marketing and sales of Vegetable Seeds.

(The name of the entity is expected to be changed soon.)



Bayer's other legal entities in India



Bayer Pharmaceuticals Pvt. Ltd. Third Party Manufacturing of Pharmaceuticals, Animal Health and Consumer Health products. Marketing and Distribution of Animal Health and Consumer Health products



Bayer Zydus
Pharma Pvt. Ltd.

Joint Venture; Marketing and Distribution of Pharmaceuticals products




Agenda

- Update Bayer global
- Overview of Bayer in India
- Bayer CropScience Ltd. (BCSL): Financial Perspective
- Update Indian Accounting Standards
- BCSL: Business Update


Revenue FY 15-16: Resilient in a challenging market environment





Profit* FY15-16: Difficulties to pass on cost increases in light of market environment






*Profit before Exceptional Items & Taxation

Balance Sheet FY15-16: Receivables under control, buyback results in lower Bank Balance





Buyback of equity shares in the amount of INR 5,060 Mio. in FY 15-16 reduced Shareholders' Funds and Bank Balance

Note: Figures in INR Mio., $\Delta\%$ y-o-y



Agenda

- Update Bayer global
- Overview of Bayer in India
- Bayer CropScience Ltd. (BCSL): Financial Perspective
- Update Indian Accounting Standards
- BCSL: Business Update

BCSL adopts Indian Accounting Standards (Ind AS) in phase I



- BCSL is covered under mandatory phase I of Ind AS implementation w.e.f. April
 1, 2016 as its net worth stood at more than INR 5,000 Mio. as of March 31, 2014
- Reporting requirement under Ind AS:

April 1, 2015¹

Opening Balance Sheet (B/S) June 30, 2016²

First Ind AS Results: Q1/FY16-17 (LR3)

- + Q1/FY15-16 restated to Ind AS
- + FY15-16 restated to Ind AS
- + Profit reconciliation

Comparative Period: FY15-16

Quarterly Ind AS Reporting: FY16-17

¹ Transition Date

April 1, 2016⁴

Start of Ind AS implementation

March 31, 2017

Ind AS Annual Accounts for FY16-17

- + FY15-16 restated to Ind AS
- + Opening B/S as on April 1, 2015 with reconciliation of Equity as on April 1, 2015 & March 31, 2016 and Profit reconciliation for FY15-16

² First Reporting Period

³ LR = Limited Review

⁴ Adoption Date

Indicative impact assessment summary FY15-16 P&L - IGAAP¹ restated to Ind AS



Figures in INR Mio.	IGAAP ¹	Ind AS Adjustment	Ind AS	Δ %
Sales 1	36,441	(8,596)	27,845	-24%
COGS ² 1	24,882	(7,850)	17,032	-32%
PAT 2 3	3,009	124	3,133	+4%
PAT to Net Sales (%)	8.3	3.0	11.3	+36%

Key impact areas:

- 1 Accounting of 'Linked Transaction' and presentation based on 'Gross vs. Net' principle (Ind AS 18 Revenue)
- Capitalisation of product registration cost (Ind AS 38 Intangible Assets)
- 3 Transaction cost for buyback of equity shares (Ind AS 109 Financial Instruments)

The assessment is an internal analysis. It is subject to audit, changes in law/ standards/ interpretations and SEBI guidelines.

Impact on quarterly published results w.r.t. excise duty presentation will be based on SEBI format.



Agenda

- Update Bayer global
- Overview of Bayer in India
- Bayer CropScience Ltd. (BCSL): Financial Perspective
- Update Indian Accounting Standards
- BCSL: Business Update

Despite slow start, above average forecast for SW monsoon





Slow start of season; good preparation & stock placement considering monsoon forecast



Crop Protection



Insecticides

 Lower acreage of rice and low infestation affected consumption



Fungicides

- Dry conditions in Q1 and lower rice acreages
- Good growth in Apple business
- Preparing for new launch



Herbicides

Good placement started for rice and corn herbicides

Seeds



Hybrid Rice Arize®

 Timely placement of stocks in the market; strong demand generation activities (1.5 mil. Farmers contacted)



Cotton Surpass®

 Retain share in difficult market thru Surpass[®] First Class and Superb sales




Millet Proagro®

Early start of season; positive sentiments in the market



Crop Outlook: June – December 2016



- Rice: Normal season with well distributed precipitation, improving commodity prices & market sentiment
- Cotton: Recovery from drought & emergence of pink boll worm segment
- Corn: Better ROI would drive the market upwards
- **Soybean**: Unattractive commodity prices, generic pressure in herbicides
- Fruits & Veg: Attractive commodity prices & demand for quality produce to drive market


Overall external drivers are positive and Bayer is well prepared to improve position



•	Rainfall and water availability	
	Crop economics for farmer	
	Market Inventories	
	Liquidity in the channel	
	Price pressure	
And the second s	Bayer portfolio strength	Witness Committee
A STATE OF THE PARTY OF THE PAR	CONTRACTOR SECURIOR S	TOTAL PROPERTY OF THE PARTY OF
	Bayer preparedness	

New Launches will play a significant role in driving the growth till 2020







"Spray Luna - feel the Experience"



A well prepared launch of a new product is "Half the Battle Won"

Training Programs

Farmers Channel Field Officers

Field Days

Demonstrations
Harvest Days
Testimonials

Campaigns

Jeep/bike Campaigns
TV/Cable/Paper Ads
Point of Sales








Integrated "Customer Interaction Management" is key to our Commercial Excellence







Summary

- Despite slow start because of late arrival of monsoon, outlook remains positive
- BCSL has strong portfolio pipeline to capture new segments
- BCSL continuously looks to increase customer responsiveness & invests to develop future farming practices, solutions and technologies

BCSL is strongly committed to "Shape the next generation of farming"





Thank you!